Tag: magrolimab
Gilead Sciences discontinues Phase 3 ENHANCE Study on higher-risk MDS due to futility
Biopharmaceutical firm Gilead Sciences (Nasdaq: GILD) has announced the termination of its Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to a lack ... Read More
Gilead Sciences wraps up $4.9bn acquisition of Forty Seven
Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been ... Read More
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn
Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, ... Read More